Table 2.
Demographic characteristics of TB patients and drug resistance profiles of Mycobacterium tuberculosis clinical isolates to ten anti-TB drugs
| Characteristics and drug resistance | New cases (n=319)
|
Previously treated cases (n=143)
|
Total cases (n=462)
|
|||
|---|---|---|---|---|---|---|
| n | % | n | % | n | % | |
|
| ||||||
| Gender | ||||||
| Male | 192 | 60.2 | 98 | 68.5 | 290 | 62.8 |
| Female | 127 | 39.8 | 45 | 31.5 | 172 | 37.2 |
| Age (years) | ||||||
| ≤15 | 4 | 1.3 | 2 | 1.4 | 6 | 1.3 |
| 16–39 | 106 | 33.2 | 40 | 27.9 | 146 | 31.6 |
| 40–59 | 110 | 34.5 | 56 | 39.2 | 166 | 35.9 |
| 60–79 | 92 | 28.8 | 41 | 28.7 | 133 | 28.8 |
| ≥80 | 7 | 2.2 | 4 | 2.8 | 11 | 2.4 |
| Resistance to first-line anti-TB drugs | ||||||
| Rifampicin | 14 | 4.4 | 63 | 44.1 | 77 | 16.7 |
| Isoniazid | 28 | 8.8 | 68 | 47.6 | 96 | 20.8 |
| Ethambutol | 13 | 4.1 | 46 | 32.2 | 59 | 12.8 |
| Streptomycin | 27 | 8.5 | 52 | 36.4 | 79 | 17.1 |
| MDR-TB | 11 | 3.4 | 55 | 38.5 | 66 | 14.3 |
| Resistance to second-line anti-TB drugs | ||||||
| Fluoroquinolones | ||||||
| Gatifloxacin | 10 | 3.1 | 13 | 9.1 | 23 | 5.0 |
| Levofloxacin | 12 | 3.8 | 24 | 16.8 | 36 | 7.8 |
| Moxifloxacin | 9 | 2.8 | 17 | 11.9 | 26 | 5.6 |
| Injectables | ||||||
| Amikacin | 5 | 1.6 | 11 | 7.7 | 16 | 3.5 |
| Capreomycin | 11 | 3.4 | 7 | 4.9 | 18 | 3.9 |
| Kanamycin | 4 | 1.3 | 9 | 6.3 | 13 | 2.8 |
| Pre-XDR-TB | 2 | 0.6 | 14 | 9.8 | 16 | 3.5 |
| XDR-TB | 1 | 0.3 | 7 | 4.9 | 8 | 1.7 |
Abbreviations: MDR-TB, multidrug-resistant TB; TB, tuberculosis; XDR-TB, extensively drug resistant TB.